• 1
    Tejani A, Ho PL, Emmett L, Stablein DM. Reduction in acute rejections decreases chronic rejection graft failure in children: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2002; 2: 142147.
  • 2
    Trompeter R, Filler G, Webb NJA et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141149.
  • 3
    Shapiro R, Scantlebury VP, Jordan ML et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999; 67: 299303.
  • 4
    Neu AM, Ho PL, Fine RN, Furth SL, Fivush BA. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study. Pediatr Transplant 2003; 7: 217222.
  • 5
    Jensen S, Jackson EC, Riley L, Reddy S, Goebel J. Tacrolimus based immunosuppression with steroid withdrawal in pediatric kidney transplantation – 4-year experience at a moderate-volume center. Pediatr Transplant 2003; 7: 119124.
  • 6
    Filler G, Webb NJA, Milford DV et al. Four-year data after pediatric renal transplantation: A randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005; 9: 498503.
  • 7
    Nashan B, Moore R, Amlot P, Schmidt A-G, Abeywickrama K, Saulillou J-P. Randomized trial of basiliximab versus placebo for control of acute rejection in renal allograft recipients. Lancet 1997; 350: 11931198.
  • 8
    Kahan BD, Rajagopalan PR, Hall ML. Reduction in the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation 1999; 67: 276284.
  • 9
    Vincenti F, Kirkman R, Light S et al. for the Daclizumab Triple Therapy Study Group. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161165.
  • 10
    Vester U, Kranz B, Testa G. Efficacy and tolerability of interleukin-2 receptor blockage with basiliximab in pediatric renal transplant recipients. Pediatr Transplant 2001; 5: 297301.
  • 11
    Offner G, Broyer M, Niaudet P et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation 2002; 74: 961966.
  • 12
    Swiatecka-Urban A, Garcia C, Feuerstein D et al. Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephrol 2001; 16: 693696.
  • 13
    Pape L, Strehlau J, Henne T et al. Single centre experience with basiliximab in paediatric renal transplantation. Nephrol Dialysis Transplant 2002; 17: 276280.
  • 14
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 15
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259263.
  • 16
    Food and Drug Administration. COSTART: Coding symbols for thesaurus of adverse reaction terms. 3rd ed. Rockville , MD : Department of Health and Human Services, Food and Drug Administration, Center for Durgs and Biologics, 1989.
  • 17
    Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents: Efficacy, side effects, and utilization. Pediatr Clin North Am 2003; 50: 12831300.
  • 18
    Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant 2005; 9: 373380.
  • 19
    Sifontis NM, Benedetti E, Vasquez EM. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc 2002; 34: 17301732.
  • 20
    Ojogho O, Sahney S, Cutler D et al. Mycophenolate mofetil in pediatric renal transplantation: Non-induction vs. induction with basiliximab. Pediatr Transplant 2005; 9: 8083.
  • 21
    Shapiro R, Nalesnik M, McCauley J et al. Post-transplant lymphoproliferative disorders (PTLD) in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68: 18511854.
  • 22
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 12891293.